Arachidonic Acid for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Arachidonic Acid for Health & Longevity

Created on 09/18/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A structural fat that is also the raw material for inflammation signals. In trained men, short-burst power rises; muscle size and strength remain unresolved. Feared harms have not appeared: no effect on blood fats, clotting or inflammation markers. Counterweights are a stronger inflammatory response to heavy training, a genetic liver signal, and clotting changes at very high doses. (Full Review)

Protocol

Standard performance dose
1,000–1,500 mg daily
Arachidonic acid from fungal single-cell oil, taken continuously alongside resistance training
Standard cognitive and mood dose
120–240 mg daily
Supplied with roughly 300 mg docosahexaenoic acid and 100 mg eicosapentaenoic acid, the mixture used in adults over 55
Split or single dose
Split with meals above 1,000 mg
Fat absorption is the limiting step; dividing the oil improves gastrointestinal tolerance without changing the endpoint reached
Time to effect
Functional changes
Weeks 4–8
Functional changes in the training trials appeared between weeks four and eight
Cognition trials
4 weeks
The cognition trials ran four weeks
Blood and membrane levels
1–2 weeks
Levels rise at any dose; red-cell content reflects roughly four months of intake

Benefits

Contraindications
  • Active rheumatoid, psoriatic or spinal inflammatory arthritis with high-sensitivity C-reactive protein above 3 mg/L
  • Active inflammatory bowel disease (Crohn's or ulcerative colitis in flare)
  • Moderate or severe persistent asthma, or any history of aspirin-exacerbated respiratory disease
  • Diagnosed fatty liver disease with liver scarring at stage F2 or above on the 0–4 fibrosis scale, or any cirrhosis
  • Inherited or acquired bleeding disorders, platelet count below 100 ×10⁹/L, or scheduled surgery within 14 days
  • Myocardial infarction within the past 90 days, or acute coronary syndrome treated with two antiplatelet drugs at once
  • Pregnancy and lactation
    •
Key Interactions
  • Aspirin and other non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, celecoxib, diclofenac)
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, rivaroxaban, clopidogrel, ticagrelor)
  • Corticosteroids (prednisone, dexamethasone, hydrocortisone)
  • Leukotriene modifiers (montelukast, zafirlukast, zileuton)
  • Omega-3 supplements (fish oil, krill oil, algal oil)
  • Gamma-linolenic acid supplements (evening primrose oil, borage oil, black currant seed oil)
  • Curcumin, boswellia, garlic, ginkgo and high-dose vitamin E
    •

Risk & Side Effects

  • High:
  • Medium: Amplified Inflammatory and Muscle-Damage Response to Hard Training; Higher Odds of Fatty Liver Disease and Cirrhosis at Genetically Elevated Levels
  • Low: Increased Platelet Reactivity at High Doses; Aggravation of Active Inflammatory Joint Disease; Displacement of Omega-3 Fats from Membrane Phospholipids
  • Speculative: Increased Membrane Susceptibility to Iron-Dependent Cell Death

Monitoring

Marker Target Why
Red-cell arachidonic acid No established target; change from own baseline, usually 10–18% of total red-cell fatty acids Confirms the supplement is actually reaching cell membranes
Omega-3 index 8% or above Guards against raising the omega-6 side while the omega-3 side stays low
Arachidonic acid to eicosapentaenoic acid ratio 1.5:1 to 3:1 One number summarizing the balance this supplement shifts
High-sensitivity C-reactive protein Below 1.0 mg/L Detects a drift toward body-wide inflammation
Complete blood count with differential Neutrophils 1.5–4.0 ×10⁹/L; platelets 175–250 ×10⁹/L Picks up the white-cell and platelet shifts seen at high intakes
Alanine aminotransferase Below 25 U/L in men, below 20 U/L in women Screens for the liver-fat signal raised by the genetic studies
Standard lipid panel Low-density lipoprotein cholesterol below 100 mg/dL; triglycerides below 100 mg/dL Confirms the neutral blood-lipid finding from the trials holds for the individual

Cadence: Full baseline before the first capsule; inflammation and blood counts at 4 weeks; fatty acid panel, lipids and liver enzymes at 4 months; then every 6–12 months for as long as supplementation continues. Any dose increase resets the schedule and calls for the 4-week pair again.

Qualitative Assessment

  • Training recovery: whether soreness, stiffness and readiness for the next hard session change over an eight-week block
  • Joint comfort: any new morning stiffness, swelling or warmth, the earliest practical signal of the inflammatory risk
  • Airway symptoms: breathlessness, night cough or increased reliever use in anyone with a history of asthma
  • Digestive tolerance: reflux, nausea or loose stools, which usually reflect the oil load rather than the fat itself
  • Bruising and bleeding: gum bleeding, nosebleeds or unexplained bruising, tracked at any dose above 1,000 mg daily
  • Energy, mood and mental clarity: the subjective counterpart to the vigor and processing-speed findings in older adults
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.